PA

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Gennari L et al. – There are three (phase II or phase III) clinical trials that clearly demonstrate efficacy and safety of this new SERM in the suppression of bone loss and the prevention of vertebral and nonvertebral fractures. Moreover, lasofoxifene treatment also reduced breast cancer risk and the occurrence of vaginal atrophy. With its increased potency and efficacy on the prevention of nonvertebral fractures lasofoxifene may be an alternative and cost–effective therapy for osteoporosis in postmenopausal women.

Related Articles

Lasofoxifene for the prevention and treatment of postmenopausal osteoporosis
Therapeutics and Clinical Risk Management, 10/16/09    Relevance Score: 91%

Today in Family Medicine...keeping you current

Persistent plaque with severe intermittent pruritus
The Clinical Advisor, 12/18/09

Why depression is hard to diagnose
The Clinical Advisor, 12/18/09

Measuring morbidity: self-report or health care records?
Family Practice, 12/18/09

Today in General Medicine...keeping you current

Comparison of the efficacy of administering a combination of ezetimibe plus fenofibrate versus atorvastatin monotherapy in the treatment of dyslipidemia
Lipids in Health and Disease, 12/18/09

A review of heart failure management in the elderly population
The American Journal of Geriatric Pharmacotherapy, 12/18/09

Phase I trial with a combination of docetaxel and 153Sm-lexidronam in patients with castration-resistant metastatic prostate cancer
Urologic Oncology: Seminars and Original Investigations, 12/18/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address